← Back to Screener
bioAffinity Technologies, Inc. Common Stock (BIAF)
Price$1.73
Value ScoreC
Growth ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)7.41%
Price vs S&P 500 (4W)-14.77%
VGM Score44.99
Market Capitalization$7.85M
All Metrics
Book Value / Share (Quarterly)$0.81
P/TBV (Annual)0.81x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.43
Price vs S&P 500 (YTD)38.45%
Gross Margin (TTM)33.08%
Net Profit Margin (TTM)-280.57%
EPS (TTM)$-11.32
10-Day Avg Trading Volume0.21M
EPS Excl Extra (TTM)$-11.32
EPS (Annual)$-8.66
ROI (Annual)-184.15%
Gross Margin (Annual)31.40%
Cash / Share (Quarterly)$0.69
Revenue Growth QoQ (YoY)-27.09%
ROA (Last FY)-136.03%
Revenue Growth TTM (YoY)-35.75%
EBITD / Share (TTM)$-4.10
Operating Margin (TTM)-204.29%
Cash Flow / Share (Annual)$-2.09
P/B Ratio2.14x
P/B Ratio (Quarterly)4.71x
Net Income / Employee (Annual)$-261,600
EV / Revenue (TTM)0.96x
Net Interest Coverage (TTM)-2.88x
ROA (TTM)-180.44%
EPS Incl Extra (Annual)$-8.66
Current Ratio (Annual)2.60x
Quick Ratio (Quarterly)1.28x
3-Month Avg Trading Volume6.11M
52-Week Price Return-79.50%
Revenue / Employee (TTM)$99,300
Tangible BV / Share (Quarterly)$0.66
P/S Ratio (Annual)1.27x
Asset Turnover (Annual)0.56x
52-Week High$13.80
EPS Excl Extra (Annual)$-8.66
26-Week Price Return15.33%
Quick Ratio (Annual)2.51x
13-Week Price Return67.96%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)1.36x
Enterprise Value$5.44M
Asset Turnover (TTM)0.64x
Revenue / Employee (Annual)$108,100
Inventory Turnover (Annual)104.16x
Pretax Margin (Annual)-241.25%
Cash / Share (Annual)$1.43
3-Month Return Std Dev285.11%
Net Income / Employee (TTM)$-278,600
ROE (Last FY)-204.87%
Net Interest Coverage (Annual)-2.32x
EPS Basic Excl Extra (Annual)$-8.66
Receivables Turnover (TTM)7.08x
Total Debt / Equity (Quarterly)0.19x
EPS Incl Extra (TTM)$-11.32
Receivables Turnover (Annual)7.57x
ROI (TTM)-163.69%
P/S Ratio (TTM)1.39x
Revenue / Share (Annual)$3.58
Tangible BV / Share (Annual)$1.46
Price vs S&P 500 (52W)-103.87%
Year-to-Date Return46.61%
5-Day Price Return-1.14%
EPS Normalized (Annual)$-8.66
ROA (5Y Avg)-174.96%
Net Profit Margin (Annual)-241.96%
Month-to-Date Return3.59%
Cash Flow / Share (TTM)$-0.95
EBITD / Share (Annual)$-5.85
Operating Margin (Annual)-171.58%
LT Debt / Equity (Annual)0.01x
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-11.32
P/TBV (Quarterly)5.82x
P/B Ratio (Annual)0.73x
Inventory Turnover (TTM)64.93x
Pretax Margin (TTM)-279.95%
Book Value / Share (Annual)$1.62
Price vs S&P 500 (13W)59.71%
Beta-1.34x
Revenue / Share (TTM)$1.26
ROE (TTM)-178.71%
52-Week Low$0.69
vGradeC
gGradeF
mGradeB
vgmGradeC
Show chart for
Analyst Recommendations
Dec 2025
Jan 2026
Feb 2026
Mar 2026
2.17
2.17
2.17
2.17
Industry Peers — R&D — Physical Sciences(15)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIAFbioAffinity Technologies, Inc. Common Stock | C | F | B | $1.73 |
| IQVIQVIA Holdings Inc. | C | B | C | $183.45 |
| INCYIncyte Genomics Inc | C | A | B | $102.38 |
| MEDPMedpace Holdings, Inc. Common Stock | D | A | B | $454.25 |
| ICLRIcon Plc | C | C | B | $149.45 |
| CRLCharles River Laboratories International, Inc. | D | D | B | $181.34 |
| ABSIAbsci Corporation Common Stock | F | F | A | $6.40 |
| NRCNRC Health Common Stock | D | D | B | $19.14 |
| OABIOmniAb, Inc. Common Stock | D | C | A | $2.48 |
| MXCTMaxCyte, Inc. Common Stock | C | D | C | $1.14 |
| ONMDOneMedNet Corp Class A Common Stock | D | C | B | $0.68 |
About
bioAffinity Technologies Inc develops noninvasive diagnostic tests and targeted cancer therapeutics, with a focus on early-stage cancer detection. The company's lead product, CyPath Lung, is a proprietary noninvasive test for detecting early-stage lung cancer. Its technology platform addresses a significant clinical market need for improved cancer diagnosis and treatment options.